Speights: Analysts also think Exelixis (NASDAQ:EXEL) could jump 50 percent or more. What do you think?
Orelli: Yeah, Exelixis is a really weird company because it has Cabometyx that's approved for a couple of different types of cancer, and it's trying to increase its sales. That will obviously increase its valuation.
Yes, and we have about 1.5B that we can use to buy more earnings that will not only increase our valuation but also help taking uncertainty away in terms of Phase I or pre-clinical pipeline candidates being able to take over the torch from Cabo in time. Biotech is low, it just needs good DD... but managament proclaim themselves experts (and reward themselves as experts). So?
Orelli: Then it's got a whole bunch of early stage pipeline candidates, they are all in Phase I or pre-clinical. You know early stage pipelines are really hard to value.
Yes, Orelli, we know, that's why the needle isn't moving… sigh…